Abstract
PEGylation, the covalent linking of PEG chains, has become the leading drug delivery approach for proteins. This technique initiated its first steps almost 40 years ago, and since then, a variety of methods and strategies for protein–polymer coupling have been devised. PEGylation can give a number of relevant advantages to the conjugated protein, such as an important in vivo half-life prolongation, a reduction or an abolishment of immunogenicity, and a reduction of aggregation. Furthermore, the technique has demonstrated a great degree of versatility and efficacy – not only PEG–protein conjugates have reached the commercial marketplace (with nine types of derivatives), but a PEG-aptamer and PEGylated liposomes are now also available. Most of this success is due to the development of several PEGylation strategies and to the large selection of PEGylating agents presently at hand for researchers. Nevertheless, this technique still requires a certain level of familiarity and knowledge in order to achieve a positive outcome for a PEGylation project. To draw general guidelines for conducting PEGylation studies is not always easy or even possible because such experiments often require case-by-case optimization. On the other hand, several common methods can be used as starting examples for the development of tailor-made coupling conditions. Therefore, this chapter aims to provide a basic introduction to a wide range of PEGylation procedures for those researchers who may not be familiar with this field.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Abuchoswki, A., Van, E., Palczuk, N.C., et al. (1977) Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 252, 3578–3581.
Jevševar, S., Kunstelj, M., Gaberc Porekar, V. (2010) PEGylation of therapeutic proteins. J. Biotechnol. 5, 113–128.
Mero, A., Veronese, F.M. (2008) The impact of PEGylation on biological therapies Biodrugs 22, 315–329.
Zalipsky, S. (1995) Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates. Bioconjug. Chem. 6, 150–165.
Veronese, F.M. (2001) Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 22, 405–417.
Snyder, S. L. and Sobocinski, P. Z. (1975) An improved 2,4,6,-trinitrobenzenesulfonic acid method for the determination of amines. Anal. Biochem. 64, 284–288.
Riddles, P.W., Blakeley, R. L., and Zarner, B. (1979) Ellman’s reagent: 5,5’-dithiobis(2-nitrobenzoic acid) a reexaminatio. Anal. Biochem. 94, 75–81.
Hanton, S. D. (2001) Mass spectrometry of polymers and polymer surfaces. Chem. Rev. 101, 527–570.
Vestling, M. M., Murphy, C. M., Fenselau, C., Dedinas, J., Doleman, M. S., Harrsch, P. B., Kutny, R., Ladd, D. L., and Olsen, M. A. (1992) Techniques in Protein Chemistry III, Academic Press, New York, pp. 477–485.
Vestling, M. M., Murphy, C. M., Keller, D. A., Fenselau, C., Dedinas, J., Ladd, D. L., and Olsen, M. A. (1993) A strategy for characterization of polyethylene glycol-derivatized proteins: a mass spectrometric analysis of the attachment sites in polyethylene glycol-derivatized superoxide dismutase. Drug Metab. Dispos. 21, 911–917.
Montaudo, G., Samperi, F., Montaudo, M. S. (2006) Characterization of synthetic polymers by MALDI-MS. Prog. Polym. Sci. 10, 1016–1020.
Zhang H., Zhang, J., Luo, Y., Wilson, J., and Miller, K. (2007) Mass spectrometric analyses of potential impurities in 20 kDa monomethoxy poly (ethylene glycol)-propionaldehyde (PEG aldehyde) raw material. AAPS Annual Meeting & Exposition.
Sivakolundu, S. G., and Mabrouk, P. A. (2003) Proton NMR study of chemically modified horse heart ferricytochrome C confirms the presence of histidine and lysine-ligated conformers in 30% acetonitrile solution. J. Inorg. Biochem. 94, 381–385.
Orsatti, L. and Veronese, F. M. (1999) An unusual coupling of poly(ethylene glycol) to tyrosine residues in epidermal growth factor. J. Bioact. Compat. Pol. 14, 429–436.
Wylie, D. C., Voloch, M., Lee, S., Liu, Y. H., Cannon-Carlson, S., Cutler, C., Pramanik, B. (2001) Carboxyalkylated histidine is a pH-dependent product of PEGylation with SC-PEG. Pharm Res. 18, 1354–1360.
Kinstler, O. B., Brems, D. N., Lauren, S. L., Paige, A. G., Hamburger, J. B. and Treuheit, M. J. (1996) Charecterization and stability of N-Terminally PEGylated rhG-CSF. Pharm. Res. 13, 996–1002.
Lee, H., Jang, I. H., Ryu, S. H., and Pack, T.G. (2003) N-Terminal site-specific mono-PEGylation of epidermal growth factor. Pharm. Res. 20, 818–825.
Kinstler, O., Molineux, G., Treuheit, M., Ladd, D. et al. (2002) Mono-N-terminal poly(ethyleneglycol)-protein conjugates. Adv. Drug Deliv. Rev. 54, 477–485.
Arakawa, T., Prestrelski, S. J., Narhi, L. O., Boone, T. C., Kenney, W. C. (1993) Cysteine 17 of recombinant human granulocyte-colony stimulating factor is partially solvent-exposed. J. Protein Chem. 12, 525–531.
Colonna, C., Conti, B., Perugini, P., Pavanetto, F., Modena, T., Dorati, R., Iadarola, P., Genta, I. (2008) Site-directed PEGylation as successful approach to improve the enzyme replacement in the case of prolidase. Int. J. Pharm. 24, 230–237.
Xian-Hui, H., Pang-Chui, S., Li-Hui, X., and Siu-Cheung, T. (1999) Site-directed polyethylene glycol modification of trichosanthin: Effects on its biological activities, pharmacokinetics, and antigenicity. Life Sic. 64, 1163–1175.
Balan, S., Choi, J., Godwin, A., Teo, I., Laborde, C. M., Heidelberger, S., Zloh, M., Shaunak, S., and Brocchini, S. (2007) Site-Specific PEGylation of Protein Disulfide Bonds Using a Three-Carbon Bridge. Bioconjug. Chem. 18, 61–76.
Zalipsky, S., and Meno-Rudolph, S. (1997) Hydrazide derivatives of polyethylene glycol and their bioconjugates. In Polyethylene glycol chemistry and biological applications, ACS symposium series 680 (Harris, J. M., and Zalipsky, S. eds.), pp. 318–341.
Gaertner, H. F., and Offord, R. E. (1996) Site-Specific Attachment of Functionalized Poly(ethylene glycol) to the Amino Terminus of Proteins. Bioconjug. Chem. 7, 38–44.
Baudys, M., Uchio, T., Mix, D., Wilson, D., and Kim, S. W. (1995) Physical stabilization of insulin by glycosylation. J. Pharm. Sci. 84, 28–33.
Esposito, P., Barbero, L., Caccia, P., Caliceti, P., D’Antonio, M., Piquet, G., Veronese, F. M. (2003) PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv. Drug Del. Rev. 55, 1279–1291
Veronese, F. M., Mero, A., Caboi, F., Sergi, M., Marongiu, C., and Pasut, G. (2007) Site-Specific PEGylation of G-CSF by Reversible Denaturation. Bioconjug. Chem. 18, 1824–1830.
Morpurgo, M., Monfardini, C., Hofland, L. J., Sergi, M., Orsolini, P., Dumont, J. M., and Veronese, F. M. (2002) Selective Alkylation and Acylation of α and ε Amino Groups with PEG in a Somatostatin Analogue: Tailored Chemistry for Optimized Bioconjugates. Bioconjug. Chem. 13, 1238–1243.
Youn, Y. S., Na, D. H., Lee, K. C. (2007) High-yield production of biologically active mono-PEGylated salmon calcitonin by site-specific PEGylation. J. Control Release 117, 371–379.
Chae, S. Y., J., C. H., Shin, H. J., Youn, Y. S., Lee, S., Lee, K.C. (2008) Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery. Bioconjug. Chem. 19, 334–341.
Sato, H. (2002) Enzymatic procedure for site-specific PEGylation. Adv. Drug Delivery. Rev. 54, 487–504.
Fontana, A., Spolaore, B., Mero, A., and Veronese, F. M. (2008) Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase. Adv. Drug Delivery Rev. 60, 13–28.
Li, N., Ziegemeier, D., Bass, L., Wang, W. (2008) Quantitation of free polyethylene glycol in PEGylated protein conjugate by size exclusion HPLC with refractive index (RI) detection. J. Pharm Biomed Anal. 48, 1332–1338.
Sims, G. E., and Snape, T. J. (1980) A method for the estimation of polyethylene glycol in plasma protein fractions. Anal. Biochem. 107, 60–63.
Seely, J. E., Richey, C. W. (2001) Use of ion-exchange chromatography and hydrophobic interaction chromatography in the preparation and recovery of polyethylene glycol-linked proteins. J. Chromatogr. A 908, 235–241.
Seely, J. E., Buckel, S. D., Green, P. D., Richey, C. W. (2005) Making site-specific PEGylation work. Biopharm Int. 18, 30–35.
Wang, Y. S., Youngster, S., Bausch, J., Zhang, R., McNemar, C., Wyss, D. F. (2000) Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry 39, 10634–10640.
Fee, C. J., Van Alstine, J. M. (2006) PEG-proteins: Reaction engineering and separation issues. Chem. Eng. Sci. 61, 924–939.
Pabst, T. M., Buckley, J. J., Ramasubramanyan, N., Hunter, A. K. (2007) Comparison of strong anion-exchangers for the purification of a PEGylated protein. J. Chromatogr. A 1147, 172–182.
Park, E. J., Lee, K. C, Na, D. H. (2009) Separation of positional isomers of mono-poly(ethylene glycol)-modified octreotides by reversed-phase high-performance liquid chromatography. J Chromatogr. A 6, 7793–7797.
Clark, R., Olson, K., Fuh, G., Mariani, M., Mortensen, D., Teshima, G., Chang, S., Chu, H., Mukku, V., Canova-Davis, E., Somers, T., Cronin, M., Winkler, M., and Wells, J. A. (1996) Long-acting Growth Hormones Produced by Conjugation with Polyethylene Glycol. J. Biol. Chem. 271, 21969–21977.
Foser, S., Schacher, A., Weyer, K. A., Brugger, D., et al. (2003) Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS). Protein Expr. Purif. 30, 78–87.
Gaberc-Porekar, V., Zore, I., Podobnik, B., Menart,V. (2008) Obstacles and pitfalls in the PEGylation of therapeutic proteins. Curr. Opin. Drug Discov. Devel. 11, 242–250.
Piedmonte, D. M., Treuheit, M. J. (2008) Formulation of Neulasta(R) (pegfilgrastim). Adv. Drug Del. Rev. 60, 50–58.
Fee, C. J (2007) Size comparison between proteins PEGylated with branched and linear poly(ethylene glycol) molecules. Biotechnol Bioeng. 98, 725–731.
Edwards, C. K., Martin, S. W., Seely, J., Kinstler, O. et al. (2003) Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases. Adv. Drug Deliv. Rev. 55, 1315–1336.
Molek, J. R., Zydney, A. L. (2006) Ultrafiltration characteristics of pegylated proteins. Biotechnol. Bioeng. 95, 474–482.
Kwon, B., Molek, J., Zydney, A. L. (2008) Ultrafiltration of PEGylated proteins: Fouling and concentration polarization effects. J. Memb. Sci. 319, 206–213.
Habeeb, A. F. S. A. (1966) Determination of free amino groups in protein by trinitrobenzenesulphonic acid. Anal.Biochem. 14, 328–336.
Riddles, P. W., Blakeley, R. L., and Zarner, B. (1983) Reassessment of Ellman’s reagent. Methods Enzymol. 91, 49–60.
Jiskoot, W., Crommelin, D. (2005) Methods for Structural Analysis of Protein Pharmaceuticals Biotechnology: Pharmaceutical Aspects. American Assoc. of Pharm. Scientists, Springer, New York.
Kusterle, M., Jevsevar, S., Gaberc-Porekar, V. (2008) Size of Pegylated Protein Conjugates Studied by Various Methods. Acta Chim. Slov. 55, 594–601.
Piedmonte, D. M., Treuheit, M. J. (2008) Formulation of Neulasta(R) (pegfilgrastim). Adv. Drug Del. Rev. 60, 50–58.
Lee, K., Moon, S. C., Park, M. O., Lee, J. T., Na, D. H., Yoo, S. D., et al. (1999) Isolation, characterizasion, and stability of positional isomers of mono-PEGylated salmon calcitonins. Pharm. Res. 16, 813–818.
Manjula, B. N., Tsai, A., Upadhya, R., Perumalsamy, K., Smith, P. K., Malavalli, A., Vandegriff, K. R., Winslow, M., Intaglietta, M., Prabhakaran, M., Friedman, J. M., and Acharya A. S. (2003) Site-Specific PEGylation of Hemoglobin at Cys-93(β): Correlation between the Colligative Properties of the PEGylated Protein and the Length of the Conjugated PEG Chain. Bioconjug. Chem. 14, 464–472.
Fee, C. J., Van Alstine, J. M. (2004) Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins. Bioconjug. Chem. 15, 1304–1313.
Kurfurst, M. M. (1992) Detection and Molecular-Weight Determination of Polyethylene Glycol-Modified Hirudin by Staining After Sodium Dodecyl-Sulfate Polyacrylamide-Gel Electrophoresis. Anal. Biochem. 200, 244–248.
Caccia, D., Ronda, L., Frassi, R., Perrella, M., Del Bavero, E., Bruno, S., Pioselli, B., Abbruzzetti, S., Viappiani, C., and Mozzarelli A. (2009) PEGylation Promotes Hemoglobin Tetramer Dissociation. Bioconjug. Chem. 20, 1356–1366.
Caserman, S., Kusterle, M., Kunstelj, M., Milunovic, T. et al. (2009) Correlations between in vitro potency of polyethylene glycol-protein conjugates and their chromatographic behaviour. Anal. Biochem. 389, 27–31.
Cindric, M., Cepo, T., Galic, N., Bukvic-Krajacic, M. et al. (2007) Structural characterization of PEGylated rHuG-CSF and location of PEG attachment sites. J. Pharm. Biomed. Anal. 44, 388–395.
Mero, A., Spolaore, B., Veronese, F. M., and Fontana, A. (2009) Transglutaminase-Mediated PEGylation of Proteins: Direct Identification by Mass Spectrometry Using a Novel Monodisperse PEG. Bioconjug. Chem. 20, 384–389.
Sergi, M., Caboi, F., Maullu, C., Orsini, G., and Tonon, G. (2009) Enzymatic techniques for PEGylation of biopharmaceuticals. In PEGylated Protein Drugs: Basic Science and Clinical Applications (Milestones in Drug Therapy) (Veronese, F.M., ed.) Birkhauser Verlag, Boston, MA, pp. 75–88.
Basu, A., Yang, K., Wang, M., Liu, S., et al. (2006) Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjug. Chem. 17, 618–30.
Stoscheck, C. M. (1990) Quantification of protein. Methods Enzymol. 182, 50–69.
Yu, P., Zheng, C., Chen, J., Zhang, et al. (2007) Investigation on PEGylation strategy of recombinant human interleukin-1 receptor antagonist. Bioorg. Med. Chem. 15, 5396–405.
Monfardini, C., Schiavon, O., Caliceti, P., Morpurgo, M., Harris, J. M., and Veronese, F. M. (1995) A branched monomethoxypoly(ethylen glicol) for protein modification. Bioconjug. Chem. 6, 62–69.
Bailon, P., Palleroni, A., Schaffer, C. A., Spence, C. L. et al. (2001) Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug. Chem. 12, 195–202.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Mero, A., Clementi, C., Veronese, F.M., Pasut, G. (2011). Covalent Conjugation of Poly(Ethylene Glycol) to Proteins and Peptides: Strategies and Methods. In: Mark, S. (eds) Bioconjugation Protocols. Methods in Molecular Biology, vol 751. Humana Press. https://doi.org/10.1007/978-1-61779-151-2_8
Download citation
DOI: https://doi.org/10.1007/978-1-61779-151-2_8
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-150-5
Online ISBN: 978-1-61779-151-2
eBook Packages: Springer Protocols